VistaGen Therapeutics, Inc. (VTGN)

VistaGen Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Year Ending	Current	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Market Capitalization	99	143	27	256	302	21
Market Cap Growth	421.73%	421.73%	-89.32%	-15.15%	1330.12%	-47.02%
Enterprise Value	-18	26	13	191	202	24
PE Ratio	-	-4.86	-0.46	-5.26	-7.13	-0.96
PS Ratio	92.81	134.11	-120.48	230.95	277.02	-
PB Ratio	0.86	1.25	2.26	3.96	3.28	-3.68
P/FCF Ratio	-5.51	-5.51	-0.55	-5.63	-24.44	-1.34
P/OCF Ratio	-5.53	-5.53	-0.55	-5.66	-25.00	-1.34
EV/Sales Ratio	24.10	24.10	-59.13	172.24	185.79	-
EV/EBITDA Ratio	-0.89	-0.89	-0.23	-4.06	-11.60	-1.15
EV/EBIT Ratio	-0.87	-0.87	-0.23	-4.00	-11.29	-1.15
EV/FCF Ratio	-0.99	-0.99	-0.27	-4.20	-16.39	-1.51
Debt / Equity Ratio	0.02	0.02	0.22	0.05	0.04	-0.71
Debt / EBITDA Ratio	-0.07	-0.07	-0.05	-0.06	-0.21	-0.20
Debt / FCF Ratio	-0.08	-0.08	-0.05	-0.07	-0.30	-0.26
Quick Ratio	23.26	23.26	3.64	11.82	24.61	0.49
Current Ratio	23.56	23.56	3.83	12.32	24.86	0.57
Asset Turnover	0.01	0.01	-0.01	0.01	0.02	0
Return on Equity (ROE)	-41.90%	-41.90%	-218.60%	-62.70%	-91.80%	637.40%
Return on Assets (ROA)	-37.60%	-37.60%	-157.80%	-52.70%	-69.40%	-268.90%
Return on Capital (ROIC)	-28.37%	-28.37%	-400.70%	-70.52%	-18.74%	1270.24%
Earnings Yield	-29.73%	-20.58%	-216.63%	-19.02%	-14.02%	-104.43%
FCF Yield	-26.20%	-18.13%	-182.55%	-17.75%	-4.09%	-74.66%
Buyback Yield / Dilution	-178.13%	-178.13%	-5.45%	-129.85%	-79.58%	-67.92%
Total Shareholder Return	-178.13%	-178.13%	-5.45%	-129.85%	-79.58%	-67.92%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).